Armata Pharmaceuticals, INC Schedule 13D activist filings
Filed when an investor crosses five percent and intends to influence the company — the activist disclosure.
AMEX
Innoviva, Inc. has expanded its financial commitment to Armata Pharmaceuticals through a new $25 million secured credit agreement.
AMEX
SCHEDULE 13D/A: Armata Extends Key Debt, Warrants, and Voting Agreements
Armata Pharmaceuticals, Inc. and Innoviva, Inc. have extended maturity dates for several credit agreements and expiration dates for warrants and a voting agreement, solidifying their financial relationship.
AMEX
Innoviva, Inc. and its subsidiary have increased their beneficial ownership in Armata Pharmaceuticals to 83.3% and provided a new $15 million secured loan.
AMEX
SCHEDULE 13D/A: Innoviva Extends Significant Funding and Debt Maturities for Armata Pharmaceuticals, Increasing Stake to 85.2%
Innoviva, Inc. and its subsidiary have provided Armata Pharmaceuticals with a new $10 million secured loan and extended the maturity dates of three existing credit agreements to March 2026, solidifying their beneficial ownership to 85.2%.